7 Things 23andMe Won't Tell You About Peptide Genetics

Your 23andMe kit directly reads about 0.02% of your genome. The other 99.98% of the data in your health report is a statistical inference, not a measurement. For ancestry and common trait questions, that works well enough. For peptide metabolism, it creates blind spots that no vendor marketing copy will explain to you.

This is not an argument that consumer DNA tests are worthless for peptide planning. Two of the most useful peptide-response genes, BDNF and COMT, are well-covered by chip tests and your existing raw file is a genuine starting point. The problem is knowing which genes your test reliably reports versus which ones it quietly estimates, and understanding when that difference actually matters for your stack.

The human genome contains around 10 million common variants. Consumer chips sample about 700,000 of them directly. The rest are inferred using a process called imputation, which looks at the markers you do have and predicts what the surrounding ones likely are, based on patterns in a reference population. When that reference population matches your ancestry and the variant is common, imputation is remarkably accurate. When it does not match, accuracy falls off sharply with no warning in your report.

Not All Peptide Genes Are Equally Hard to Measure

Before getting into what consumer tests miss, here is how the difficulty breaks down across the genes that matter most for peptide protocols. There are three tiers, and knowing which tier your gene of interest falls into tells you exactly what tool you need.

7 Things Your DNA Test Will Not Tell You About Peptide Genetics

1. Consumer Tests Directly Read 0.02% of Your Genome. The Rest Is a Statistical Inference.

This is the foundational fact that every other limitation flows from. A 2024 study in Frontiers in Pharmacology (PMC10961362) validated a chip-based pharmacogenomics workflow across 503 SNP positions and achieved 99.39% overall sensitivity. Impressive, until you read the fine print: 33 of those 503 positions were imputed, not directly measured, and the imputed sites showed meaningfully lower callability, especially for rare alleles.

What this means for you: Most of the variant calls in your consumer health report are predictions, not measurements. For common variants shared across millions of people, those predictions are usually right. For rare variants that govern drug and peptide metabolism, the prediction often fails silently, returning a false-normal result with no warning flag in your report.

2. CYP2D6 Ultra-Rapid Metabolizer Status Is Completely Invisible to Chip Tests

CYP2D6 metabolizes roughly 25% of all pharmaceutical drugs. It also has more than 150 known variants, including copy-number variants where you might carry one, two, three, or even four copies of the gene. If you carry an extra copy, you clear compounds so fast that standard doses never reach effective levels. If you carry a deletion, compounds accumulate at potentially harmful concentrations.

A 2023 study in Genes (PMC10606650) reviewed commercial antidepressant pharmacogenomics panels and found that no panel fully covered CYP2D6. Consumer chip tests perform even worse: copy-number variants are structural changes that require a completely different assay type. Chips simply cannot detect them. Your 23andMe result will report you as a normal metabolizer whether you have one copy of CYP2D6 or four.

"Copy number variation in CYP2D6 represents one of the most clinically significant gaps in current genotyping approaches. The functional consequence of gene duplication cannot be inferred from SNP data alone."

Genes, 2023 (PMC10606650)

3. CYP3A4 Has a "Missing Heritability" Problem Nobody Has Solved

CYP3A4 metabolizes approximately 50% of known drugs and many peptide-adjacent compounds, including testosterone, DHEA, and statins that appear in common peptide stacks. Most of its functional variation comes from rare variants with population frequencies below 1%. These are poorly captured by consumer chip tests and by most clinical pharmacogenomics panels.

A 2013 paper in Pharmacogenomics (PMC3580761) named this the "missing heritability" problem for CYP3A4: twin studies clearly show a strong genetic component to enzyme activity, but genotyping fails to explain most of the variance. More than a decade later, the problem remains unsolved. If a test company claims it can accurately predict your CYP3A4 metabolizer status from chip data, it is overstating what the science supports. For protocol-level guidance on navigating this, see the detailed breakdown on CYP3A4 slow metabolizers and peptide dosing.

4. Imputation Accuracy Collapses for Non-European Ancestry

The statistical models used to infer missing SNPs are built from reference panels drawn primarily from European populations. A 2022 study in Frontiers in Genetics (PMC8762119) directly compared SNP chip imputation against low-coverage whole-genome sequencing across diverse ancestries and found that rare variant recovery dropped significantly in non-European cohorts compared to European ones.

This matters because pharmacogenomically-relevant CYP variants are often population-specific. A 2021 study in Frontiers in Genetics (PMC8506148) documented worse clinical outcomes on genotype-guided dosing when ancestry-specific variants were not included in the panel. If your ancestry is not primarily Northern European, your consumer test results carry additional uncertainty that no report will flag for you. The data looks the same in your report whether it was directly measured or inferred from a mismatched reference.

5. The FDA Restricts Which Health Variants 23andMe Is Allowed to Report to You

This is the most underappreciated limitation. The 23andMe health reports you see are not simply the raw output of their chip. They are a curated subset shaped by FDA authorization decisions made in 2017 and updated since. The agency approved 23andMe to report a specific list of variants. Anything outside that list is not shown to consumers, regardless of whether the variant is on the chip or clinically relevant to your protocol.

A 2017 study in BMC Medical Genomics (PMC5477417) that specifically examined pharmacogenetic testing through 23andMe documented this gap directly: the platform genotypes many clinically relevant pharmacogenomic positions but does not report them to users under the consumer authorization framework. Your raw data file often contains these calls. The consumer-facing health report simply does not surface them. See the 23andMe peptide guide for how to extract your raw file and which positions to check manually.

6. Chip Sensitivity for Rare Pathogenic Variants Is Only 34.6%

A 2021 study in the BMJ (PMC7879796) used UK Biobank data to test how well SNP chip genotyping detected BRCA1 and BRCA2 pathogenic variants. Sensitivity was 34.6% and positive predictive value was 4.2%. That means 96 of every 100 positive results were false positives. For variants with a population frequency below 0.001%, sensitivity collapsed to between 4.4% and 29.5%. These numbers apply to well-characterized BRCA variants in a large, high-quality dataset. For rare peptide-relevant variants in smaller populations, performance is worse.

This is not a 23andMe-specific failure. It is a structural limitation of chip-based genotyping for rare variant detection. Any vendor using chip data to call rare variants, whether it is a consumer health company or a specialist peptide test, faces the same constraint.

7. BDNF Val66Met and COMT Val158Met Are Actually Well-Covered. Here Is the Good News.

Consumer chip tests get something genuinely right that no marketing copy explains clearly: simple biallelic SNPs with high population frequency are accurately called. BDNF Val66Met (rs6265) and COMT Val158Met (rs4680) fall squarely into this category. They are accurately genotyped by 23andMe, AncestryDNA, and MyHeritage on every chip version those companies have shipped.

These two variants answer the most actionable peptide questions. BDNF Val66Met tells you how your brain produces activity-dependent neurotrophin, which shapes whether nootropic peptides like Semax and Selank have the substrate to work with. COMT Val158Met tells you how fast your prefrontal cortex clears dopamine, which determines whether dopaminergic peptides help or hurt your cognition and anxiety baseline. See the DNA-first decision framework for how to translate those calls into a protocol. COL1A1 rs1800012, which predicts soft tissue repair capacity and response to BPC-157 repair protocols, is also reliably covered by consumer chips.

Your consumer DNA test data is a genuine starting point. The limitation is not that the data is wrong. The limitation is that no consumer report tells you which parts to trust and which to treat with caution. That distinction is what separates useful genetic information from noise.

How Do 23andMe, Clinical PGx Panels, and Specialist Reports Compare?

Once you understand what chip tests can and cannot do, the practical question is which tool to reach for at each layer of your protocol. Clinical pharmacogenomics panels like GeneSight and Genomind use targeted sequencing designed specifically to capture copy-number variants and rare alleles that consumer chips miss. They run through CLIA-certified labs and cost $200 to $500 out of pocket if insurance does not cover them.

Gene or Feature	23andMe / AncestryDNA	Clinical PGx Panel	PeptidesDNA Report
BDNF Val66Met (rs6265)	Yes, accurate	Yes, accurate	Yes, with peptide interpretation
COMT Val158Met (rs4680)	Yes, accurate	Yes, accurate	Yes, with peptide interpretation
COL1A1 rs1800012 (tissue repair)	Yes, accurate	Rarely included	Yes, with peptide context
CYP2D6 copy-number variants	No	Yes (most panels)	Flagged where clinically relevant
CYP3A4 rare variants	No	Partial	Flagged as limited-data zone
Peptide-specific interpretation	No	No	Yes, per peptide category
FDA-restricted variant filtering	Yes (hides some calls)	No restriction	Raw data layer available
Ancestry bias disclosure	Not flagged per variant	Varies by lab	Disclosed per variant
Cost	$99 to $299	$200 to $500 OOP	$99 with raw data upload

The practical read: clinical PGx panels are the right choice if you are co-managing peptides with pharmaceutical drugs that run through CYP2D6 or CYP3A4 pathways, or if you have a history of unusually strong or weak medication responses. For pure peptide optimization focused on BDNF, COMT, and collagen genetics, your existing consumer test raw file is the right starting tool and there is no benefit to upgrading until you hit the CYP layer.

How to Actually Use Your DNA Data for Peptide Planning

Start with what you have. If you already own a 23andMe or AncestryDNA file, download the raw data first. Do not rely only on the consumer health report, which hides FDA-restricted variants. The raw file contains the underlying calls. Upload it to a peptide-specific interpretation service, or check BDNF rs6265 and COMT rs4680 directly using any raw data browser. Both appear in your file as directly measured calls, not inferred ones.

If you have never tested: a consumer chip test is still the cost-effective first step. It covers the high-leverage wellness SNPs accurately. Add a clinical PGx panel as a second step only if your protocol includes drug co-administration or if you have experienced surprising medication responses historically.

One additional consideration: the 23andMe bankruptcy in March 2025 resulted in the genetic profiles of 15 million users being acquired for $305 million by a private entity after the company collapsed. No federal statute protects genetic data in a corporate bankruptcy. Downloading your raw file and using it through a GDPR-compliant interpretation service is the lower-risk approach compared to leaving your genome in a platform's cloud indefinitely. The data is equally useful either way. The difference is who controls it.